PMID- 24477670
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140622
LR  - 20211021
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 5
IP  - 1
DP  - 2014 Jun
TI  - Type 2 diabetes mellitus management and body mass index: experiences with 
      initiating insulin detemir in the a1chieve study.
PG  - 127-40
LID - 10.1007/s13300-014-0054-2 [doi]
AB  - INTRODUCTION: This sub-analysis of the A1chieve study aimed to examine the safety 
      and efficacy of insulin detemir (IDet) initiation over 24 weeks in relation to 
      baseline body mass index (BMI) in people with type 2 diabetes mellitus (T2DM). 
      METHODS: A1chieve was a 24-week non-interventional study to assess the safety and 
      efficacy of insulin analogs in routine practice. This sub-analysis included 
      insulin-naive patients who initiated IDet therapy based on their physicians' 
      decision. Patients were stratified according to baseline BMI (Group I, 
      <25.0 kg/m(2); Group II, 25.0 to <30.0 kg/m(2); Group III, 30.0 to <35.0 kg/m(2); 
      Group IV >/=35.0 kg/m(2)). Safety and efficacy variables were assessed over 
      24 weeks. RESULTS: Overall, 10,650 insulin-naive patients were included (3,045 
      patients in Group I, 4,186 patients in Group II, 2,365 patients in Group III, and 
      1,054 patients in Group IV). Four serious adverse drug reactions (SADRs) were 
      reported. From baseline to Week 24, there was no statistically significant 
      difference in the proportion of patients reporting overall hypoglycemia in Group 
      I (4.0% vs. 4.4%), while a significant decrease in Group II (4.8% vs. 4.0%, 
      p = 0.0335) and significant increases in Groups III and IV (3.3% vs. 5.4% and 
      3.4% vs. 7.0%, respectively, p < 0.001) were noted. The mean body weight 
      increased from baseline to Week 24 in Group I (60.7 +/- 8.4 vs. 61.8 +/- 8.5 kg) and 
      reduced in Groups II, III, and IV (74.5 +/- 9.2 vs. 74.2 +/- 9.2 kg, 87.4 +/- 10.3 vs. 
      86.0 +/- 9.8 kg, and 102.2 +/- 14.3 vs. 100.1 +/- 14.2 kg, respectively; all 
      p < 0.001). Significant improvements were noted in glycemic parameters, systolic 
      blood pressure, and lipids over 24 weeks, irrespective of baseline BMI status. 
      CONCLUSION: IDet therapy was associated with improved glycemic control and a low 
      number of SADRs. Greater weight loss was observed with higher BMI.
FAU - Khamseh, Mohammed E
AU  - Khamseh ME
AD  - Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran 
      University of Medical Sciences, Tehran, Iran, khamseh.m@iums.ac.ir.
FAU - Prusty, Vinay
AU  - Prusty V
FAU - Latif, Zafar
AU  - Latif Z
FAU - Gonzalez-Galvez, Guillermo
AU  - Gonzalez-Galvez G
FAU - Dieuzeide, Guillermo
AU  - Dieuzeide G
FAU - Zilov, Alexey
AU  - Zilov A
LA  - eng
PT  - Journal Article
DEP - 20140130
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC4065301
EDAT- 2014/01/31 06:00
MHDA- 2014/01/31 06:01
PMCR- 2014/01/30
CRDT- 2014/01/31 06:00
PHST- 2013/10/07 00:00 [received]
PHST- 2014/01/31 06:00 [entrez]
PHST- 2014/01/31 06:00 [pubmed]
PHST- 2014/01/31 06:01 [medline]
PHST- 2014/01/30 00:00 [pmc-release]
AID - 54 [pii]
AID - 10.1007/s13300-014-0054-2 [doi]
PST - ppublish
SO  - Diabetes Ther. 2014 Jun;5(1):127-40. doi: 10.1007/s13300-014-0054-2. Epub 2014 
      Jan 30.